Veeva Pulse Field Insights: Europe

Key Findings in Europe

Digital content boosts promotional response. U.S. data show a global trend that digital content used during video and in-person meetings more than doubles the promotional response over meetings that don’t share content.

Successful teams use content seven times more. Field reps that use digital content the most outpace seven times others who don’t frequently leverage it. European field teams have room for growth, currently sharing digital content in just 29% of meetings, despite its proven effectiveness.

High-impact content drives HCP engagement. In the last year, biopharmas created significantly more content. Yet, of all the content created, 76% is rarely or never used in Europe. This indicates a need for companies to focus their content strategy on developing fewer assets that are proven effective in advancing relevant engagements with HCPs.

Digital Content More Than Twice as Effective in Driving Promotional Response

Promotional impact of digital content

In-person and video meetings

Veeva Pulse and Compass data, U.S.,

January 2019–June 2021

Percent of rep-HCP meetings using digital content 

In-person and video

Veeva Pulse data,
 April 2022–February 2023

HCP Engagement Metrics — Europe

Engagement Channel Mix Over Time

Veeva Pulse data, January–December 2022

HCP Video Meeting Duration

Veeva Pulse data, October–December 2022

FULL REPORT

Go to article: Home | Pathbreakers: The journey of first genericsGo to article: Editor's letterGo to article: ContentsGo to article: wek-tec Company InsightGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: VeevaGo to article: In DepthGo to article: Pathbreakers: The journey of first genericsGo to article: Managed access programmes: Reaching patients in needGo to article: Insulin pricing in flux as major pharma players take actionGo to article: As RSV vaccine approvals loom, regulators need to devise vaccination strategiesGo to article: Build API facilities in Central and Eastern Europe to fix drug shortages, says report Go to article: CfPIEGo to article: BEA TechnologiesGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: The state of cybersecurity in 2023Go to article: The history of cybersecurityGo to article: The impact of cybersecurity on the pharmaceutical industryGo to article: Case studies: cybersecurity in the pharmaceutical industryGo to article: Latest news: cybersecurity in pharma Go to article: Q&A with GlobalData thematic analystGo to article: Key cybersecurity trends in PharmaGo to article: Cybersecurity in pharma: Securing the future Go to article: Deal activity related to cybersecurity in the pharmaceutical industry since 2018Go to article: Cybersecurity hiring trends in the global pharmaceutical industry since 2020Go to article: Cybersecurity patent applications in the global pharma industry since 2020Go to article: Mentions of cybersecurity in pharma industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue